Russell Investments Group Ltd. Boosts Stock Position in Insulet Co. (NASDAQ:PODD)

Russell Investments Group Ltd. lifted its position in Insulet Co. (NASDAQ:PODD) by 8.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 74,902 shares of the medical instruments supplier’s stock after buying an additional 5,728 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.11% of Insulet worth $21,613,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of PODD. Moneta Group Investment Advisors LLC increased its holdings in Insulet by 101,333.5% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 1,300,377 shares of the medical instruments supplier’s stock worth $382,818,000 after purchasing an additional 1,299,095 shares during the period. Gateway Advisory LLC acquired a new stake in shares of Insulet in the 1st quarter valued at about $550,000. Geode Capital Management LLC boosted its position in shares of Insulet by 55.4% in the 1st quarter. Geode Capital Management LLC now owns 1,486,725 shares of the medical instruments supplier’s stock valued at $473,166,000 after purchasing an additional 529,926 shares during the period. Clearbridge Investments LLC raised its stake in Insulet by 38.8% during the 1st quarter. Clearbridge Investments LLC now owns 1,696,822 shares of the medical instruments supplier’s stock valued at $452,016,000 after acquiring an additional 474,545 shares during the last quarter. Finally, Norges Bank purchased a new stake in Insulet during the 4th quarter valued at approximately $105,275,000.

Insulet Stock Up 4.1 %

NASDAQ:PODD opened at $181.26 on Tuesday. The company has a market capitalization of $12.66 billion, a price-to-earnings ratio of 106.00, a price-to-earnings-growth ratio of 2.34 and a beta of 0.83. Insulet Co. has a one year low of $125.82 and a one year high of $335.91. The stock has a 50-day simple moving average of $154.02 and a 200 day simple moving average of $225.54. The company has a debt-to-equity ratio of 2.26, a quick ratio of 2.35 and a current ratio of 3.26.

Insider Buying and Selling

In other Insulet news, Director Shacey Petrovic sold 20,000 shares of Insulet stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $164.33, for a total value of $3,286,600.00. Following the completion of the transaction, the director now directly owns 2,567 shares in the company, valued at $421,835.11. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CEO James Hollingshead bought 5,550 shares of the firm’s stock in a transaction on Monday, August 28th. The stock was bought at an average cost of $181.41 per share, for a total transaction of $1,006,825.50. Following the completion of the purchase, the chief executive officer now directly owns 34,177 shares in the company, valued at approximately $6,200,049.57. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Shacey Petrovic sold 20,000 shares of Insulet stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $164.33, for a total value of $3,286,600.00. Following the completion of the transaction, the director now owns 2,567 shares of the company’s stock, valued at $421,835.11. The disclosure for this sale can be found here. Insiders own 0.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on PODD shares. SVB Leerink started coverage on Insulet in a research note on Monday, October 16th. They set an “outperform” rating and a $184.00 target price for the company. Jefferies Financial Group raised Insulet from a “hold” rating to a “buy” rating and dropped their price objective for the company from $260.00 to $240.00 in a research note on Monday, October 2nd. Citigroup upgraded Insulet from a “neutral” rating to a “buy” rating and decreased their price objective for the stock from $273.00 to $265.00 in a report on Monday, August 21st. Barclays reduced their target price on Insulet from $329.00 to $257.00 and set an “equal weight” rating on the stock in a report on Thursday, August 10th. Finally, Robert W. Baird lowered Insulet from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $320.00 to $219.00 in a research report on Monday, August 21st. Seven investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $254.80.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.